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Atherosclerosis is a chronic disease of the arteries whose development involves a local inflammatory response
characterized by the activation of different cells such as macrophages,T-lymphocytes, smooth muscle cells
(SMCs) and endothelial cells (ECs).This review will summarize recent evidence for a modulatory role of the
nuclear receptor ROR-α in cardiovascular disease.
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Introduction
Cardiovascular disease (CVD) is a major cause of death
in western societies. Atherosclerosis is an important
cause of CVD and its clinical outcomes, myocardial
infarcts, stroke and angina pectoris. Atherosclerosis is a
chronic disease of the arteries. Its development involves
a local inflammatory response characterized by the
activation of different cells such as macrophages,
T-lymphocytes, smooth muscle cells (SMCs) and
endothelial cells (ECs) [Besnard et al., 2002; Ross, 1990].
Dyslipidemia is among the most important risk factors for
CVD.There is convincing evidence from epidemiological
and intervention studies that elevated low-density
lipoprotein, reduced high-density lipoprotein cholesterol
and elevated triglycerides in plasma are positively
correlated to the progression of atherosclerosis and CVD
[Assmann et al., 1998; Sprecher, 1998].
Inflammation, induced by locally elevated levels of
atherogenic lipoproteins, is now considered as an
important factor in the initiation of the lesions and their
progression to the final stages leading to acute thrombotic
complications and subsequent clinical events. Elevated
circulating levels of inflammatory markers, such as CRP
and IL6, are associated with an increased cardiovascular
risk [Blake and Ridker, 2003]. Activated cells in the
lesions, including ECs, SMCs and macrophages, produce
an inflammatory response to these inflammatory stimuli
via the activation of transcription factors, such as nuclear
factor kappa-B (NFB), a redox-sensitive transcription
factor regulating a battery of inflammatory genes.
Activation of NFB induces gene programs leading to
transcription of factors that promote local inflammation,
such as leukocyte adhesion molecules, cytokines, and
chemokines [Valen et al., 2001]. Rupture of advanced,
unstable plaques provokes an atherosclerotic event
leading to clinical sequelae. In the advanced plaque,
neovascularisation occurs via angiogenesis that may
influence plaque stability. Angiogenesis occurs under
various pathological situations with an ischemic
component [Carmeliet, 2000].
ROR-α (NR1F1)
RAR-related orphan receptors (RORs) constitute a
subfamily of the nuclear receptors that includes three
members: ROR-α, RORβ and RORγ. ROR-α is expressed
in several organs and tissues, especially in skeletal
muscle, fat tissue, retina, spleen, testis and the Purkinje
cells in cerebellum [Giguere, 1999; Jetten et al., 2001;
Lau et al., 1999]. RORβ, is highly expressed in different
parts of the neurophotoendocrine system, the pineal
gland, the retina, and suprachiasmatic nuclei, suggesting
a role in the control of circadian rhythm. RORγ, is most
highly expressed in the thymus and is shown to play an
important role in thymopoiesis [Giguere, 1999; Jetten et
al., 2001]. As most nuclear receptors, ROR-α is structured
in a series of domains termed, from N- to C-terminus, A
through F (see Figure 1). Four different isoforms are
generated from the ROR-α gene, which differ in the first
two domains, A and B.These splice variants are termed
1 through 4 (ROR-α4 has also been termed RZR).The
C region contains the DNA binding domain (DBD), with
two zinc finger motifs and a C-terminal extension of this
region, called the T/A box, which assures contact to DNA
and confers recognition specificity of the response
element 5' nucleotides.
ROR-α binds either as a monomer to a ROR response
element (RORE) composed of a 6 bp AT-rich sequence
5' to the consensus half-site AGGTCA core or as a
homodimer to a direct repeat of the AGGTCA core
separated by two base pairs (DR2 sites). Interestingly,
the transcriptional repressor Rev-erbα, another nuclear
receptor, binds to the same response elements [Harding
et al., 1997; Raspe et al., 2002]. As a means to identify
ROR-α target genes, RORE sites have been identified
by homology searches in many gene promoters [Schrader
et al., 1996]. Among the functionally characterised ROR-α
target genes are apoC-III , Rev-erbα , and PPAR γ
[Sundvold and Lien, 2001], which are especially induced
by ROR-α1. Moreover, ROR-α4, in concert with HNF6,
activates the α-fetoprotein gene in liver cells [Nacer-Cherif
et al., 2003].
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Review  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1. Alignment of different human ROR-α isoforms. Similar sequences are shown in white and green. Distinct sequences in hatched boxes.
The coding sequence from ATG to TAA and the corresponding numbers for nucleotides are shown, respectively.
Ligands
Kallen et al. have determined the crystal structure of the
ROR-α ligand binding domain (LBD). Structure analysis
revealed the presence of a ligand in the binding pocket,
which was identified as cholesterol. ROR-α transcriptional
activity could be modulated by changes in intracellular
cholesterol levels or mutation of ROR-α amino acid
residues involved in cholesterol binding. Among
cholesterol derivatives capable of activating ROR-α, the
most active form identified was cholesterol-sulfate.This
suggests that ROR-α could play a key role in the
regulation of cholesterol homeostasis and may thus be
a potential drug target for cholesterol-related diseases
[Kallen et al., 2002]. Other ligands suggested to bind
ROR-α are melatonin [Missbach et al., 1996] and
synthetic compounds like certain thiazolidinediones
[Wiesenberg et al., 1998], but these observations remain
unclear.
Coregulators
So far, only a limited number of co-activators like, GRIP-1
and PBP, have been shown to interact with ROR-α [Atkins
et al., 1999]. Mutational analyses have also revealed that
the hinge and ligand binding domains of ROR-α may
interact with the nuclear co-repressors N-CoR and SMRT
[Harding et al., 1997].Tissue-specific interactions with
specific co-factors may constitute the molecular basis for
distinct physiological activities of ROR-α [Harding et al.,
1997].
Intracellular signalling pathways driven by changes in
calcium levels also modulate ROR-α activity and a
calcium/calmodulin-independent protein kinase, CaMKIV,
potentiates ROR-α transcriptional activity. However, no
direct phosphorylation of the ROR-α protein has been
shown in vitro [Kane and Means, 2000].
The ROR-α-deficient staggerer mouse
The staggerer mouse that carries a deletion within the
ROR-α gene, has been instrumental in most studies on
the physiological function of ROR-α.This model mouse
is characterized by severe neuronal and immune
abnormalities [Hamilton et al., 1996; Herrup and Mullen,
1979;Trenkner and Hoffmann, 1986].
Control of inflammation
Staggerer mice have defects in thymus development and
display a prolonged humoral response [Trenkner and
Hoffmann, 1986]. At the cellular level, an overproduction
of inflammatory cytokines has been observed in
macrophages from staggerer mice [Kopmels et al., 1992].
This inflammatory and immunomodulatory role of ROR-α
has since been linked to a direct action of ROR-α on the
NF-B system [Delerive et al., 2001]. Ectopic expression
of ROR-α1 in human primary SMCs inhibits
TNFα-induced IL-6, IL-8 and COX-2 expression. ROR-α1
negatively interferes with the NF-B signalling pathway by
reducing p65 translocation.This action of ROR-α1 on
NF-B is associated with the transcriptional induction of
IBα, the major inhibitory protein of the NF-B signalling
pathway [Besnard et al., 2001; Delerive et al., 2001].
Role in vascular function
These observations along with the recognition of
atherosclerosis as an inflammatory disease of the vessel
wall, has prompted to analyse the susceptibility of the
staggerer mice to atherosclerosis.When maintained on
an atherogenetic diet, sg/sg mice develop a severe
atherosclerosis and hypoalphalipoproteinemia.This
decrease in HDL level is associated with lowered apoA-I
expression in the intestine but not in the liver [Mamontova
et al., 1998]. During recent years additional physiological
roles have been identified for ROR.These include a role
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pressure as a consequence of altered control of
vasomotor tone in small resistance arteries [Besnard et
al., 2002]. Ischemia-induced angiogenesis is also
enhanced in staggerer mice [Besnard et al., 2001] and
expression of endothelial NO synthase (eNOS) protein
is increased in ischemic tissues of staggerer mice
[Besnard et al., 2001].
Figure 2. Metabolic and cardiovascular functions of ROR-α. See
text for more details.
Lipoprotein metabolism
Staggerer mice display lowered plasma HDL cholesterol
levels associated with decreased plasma apoA-I and
apoA-II concentration. Expression of the murine apoA-I
gene is lowered in the intestine, suggesting a
physiological role for ROR-α in the intestine [Vu-Dac et
al., 1997]. However, the regulation of apoA-I gene
expression and, as a consequence, HDL metabolism,
appears to species-specific. Indeed the RORE in the
rodent apoA-I promoter is not conserved in the human
gene [Vu-Dac et al., 1997]. However, ROR-α may control
plasma TG metabolism both in rodents and humans.
ROR-α positively regulates expression of the mouse and
human apoC-III genes and in human HepG2 cells
ROR-α1 activates the apo C-III gene promoter. Moreover,
sg/sg mice have reduced plasma triglyceride and apo
C-III levels [Raspe et al., 2001].
Conclusion
Altogether, these observations suggest a modulatory role
for ROR-α in the control of lipid metabolism and
inflammation related to CVD (Figure 2).The finding that
cholesterol and/or its derivatives could be ligands for
ROR-α opens the possibility to screen for synthetic
agonists that may be useful to treat and prevent CVD.
However, it will be necessary to develop compounds with
dissociated activities, since a full agonist, while potentially
exerting anti-inflammatory activities, may be expected to
induce apoC-III expression and increase TG
concentration. Such action on TG levels may increase
the atherosclerotic risk profile. A possible application of
ROR-α agonists could be in the treatment of acute
inflammatory diseases.
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